Public Employees Retirement System of Ohio Has $7.70 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Public Employees Retirement System of Ohio decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 51,548 shares of the biopharmaceutical company’s stock after selling 3,869 shares during the period. Public Employees Retirement System of Ohio’s holdings in Alnylam Pharmaceuticals were worth $7,704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Quent Capital LLC boosted its stake in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 123 shares during the period. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals in the 1st quarter worth $30,000. GAMMA Investing LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth $52,000. Finally, V Square Quantitative Management LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $261.00, for a total value of $1,851,273.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the transaction, the chief financial officer now directly owns 28,892 shares of the company’s stock, valued at approximately $6,674,052. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $19,168,101. The disclosure for this sale can be found here. Insiders have sold a total of 74,450 shares of company stock valued at $15,287,984 in the last three months. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ALNY shares. TD Cowen upped their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Wells Fargo & Company upped their target price on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 25th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $283.00 to $357.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Finally, HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $256.73.

Alnylam Pharmaceuticals Stock Up 0.3 %

Shares of ALNY stock traded up $0.72 on Tuesday, reaching $237.00. The stock had a trading volume of 34,622 shares, compared to its average volume of 873,509. The firm’s 50-day moving average is $200.71 and its two-hundred day moving average is $172.70. The firm has a market capitalization of $29.98 billion, a price-to-earnings ratio of -88.16 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The firm’s revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.40) earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.